Intelligence Β· Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors β phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β searchable for business development and competitive intelligence.
-
GENTAMICIN , CEFAZOLIN , VANCOMYCIN , TEDIZOLID , PRISTINAMYCIN , SULFAMETHOXAZOLE AND TRIMETHOPRIM , CEFOTAXIME, CEFTAROLINE FOSAMIL , AMOXICILLIN , OFLOXACIN , CLINDAMYCIN , TIGECYCLINE , LINEZOLID , AMIKACIN , LYMECYCLINE , CEFTRIAXONE , TEICOPLANIN , DOXYCYCLINE , PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , Xydalba 500 mg powder for concentrate for solution for infusion, LEVOFLOXACIN , DELAFLOXACIN , CIPROFLOXACIN , CLOXACILLIN , OXACILLIN , DAPTOMYCIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , RIFAMP
Pari Pharma GmbH
Catheter related bloodstream infections due to Staphylococcus aureus
1 trial -
PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion
Pari Pharma GmbH
Patients hospitalized for allogeneic hematopoietic stem cell transplantation
1 trial -
RIFAXIMIN , VANCOMYCIN , Entyvio 300 mg powder for concentrate for solution for infusion, AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CIPROFLOXACIN , METRONIDAZOLE
Takeda Pharmaceuticals International AG
Active Chronic Pouchitis
1 trial -
TRIAMCINOLONE , VANCOMYCIN , CEFAZOLIN , BETAMETHASONE , OMEPRAZOLE , JNJ-74765340, JNJ-74765340, DEXAMETHASONE , CEFUROXIME
Janssen-Cilag International N.V.
X-Linked Retinitis Pigmentosa caused by mutations in the RPGR gene
1 trial -
AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP
Pari Pharma GmbH
Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission
1 trial -
VANCOMYCIN , MaaT013
Pharma Mar S.A.
Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
1 trial -
Vancomycin
Cardiff Oncology
Late Onset Neonatal Sepsis
1 trial -
Vancomycin Pre-Treatment
Seres Therapeutics
Ulcerative Colitis
1 trial -
Vancomycin and bowel lavage
China SXT Pharmaceuticals
Slow Transit Constipation
1 trial -
aerosolized vancomycin or gentamicin
Nektar Therapeutics UK Limited
Ventilator Associated Pneumonia
1 trial -
Vancomycin Pre-Treatment
Seres Therapeutics
Allogeneic Hematopoietic Stem Cell Transplantation
1 trial -
CEFEPIME, TEICOPLANIN, METRONIDAZOLE, METRONIDAZOLE, MEROPENEM, TAZOBACTAM, VANCOMYCIN, LEVOFLOXACIN, CIPROFLOXACIN, CEFTAZIDIME, METRONIDAZOLE, CIPROFLOXACIN, LEVOFLOXACIN, AMIKACIN, CIPROFLOXACIN, PIPERACILLIN
Institut fΓΌr biomedizinische Analytik NMR-Imaging GmbH
Infectious diseases
1 trial -
Vancomycin
First Tracks Biotherapeutics
Blood Stream Infections
1 trial -
Vancomycin
United Therapeutics Europe Ltd
Open Fracture
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1β3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources